Clene Inc. (CLNNW) 株式分析

企業概要

Clene Inc. is a clinical-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's primary focus lies in advancing its lead drug candidate, CNM-Au8, which is currently undergoing evaluation in various clinical trials, including a completed Phase 2 platform study. This business model places Clene Inc. within the pharmaceutical sector, although specific industry classification data is not publicly disclosed in the available records. The company currently maintains an operational scale supported by a workforce of 75 employees, reflecting a lean organizational structure typical of early-stage biotechnology firms. Given that the market capitalization and annual revenue figures are not provided in the dataset, the company's financial positioning relative to its broader peer group cannot be quantitatively assessed based on the available valuation metrics.

財務健全性

Clene Inc. reported a trailing twelve-month (TTM) revenue of $214,000, yet the company recorded a net income of $-30,496,000 for the same period. This significant disparity between the modest revenue figure and the substantial net loss highlights a cost structure where operating expenses vastly exceed current income generation, a common characteristic in the clinical development phase of biopharmaceutical ventures. The company's EBITDA stands at $-22,703,000, further indicating that cash flows from core operations are insufficient to cover the costs of revenue generation and overhead. Free cash flow for the trailing twelve months was recorded at $-13,295,375, which signifies a negative liquidity position where the company is consuming more cash than it generates from its operations. The gross margin is reported at 82.2%, suggesting that the cost of goods sold is low relative to revenue, while the operating margin of -37653.3% and profit margin of 0.0% reflect severe operational inefficiencies or heavy investment in research and development that suppresses bottom-line profitability. In terms of balance sheet leverage, the company holds $7.92M in cash against $21.31M in debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of positive equity data in the current dataset. The current ratio is 1.53, indicating that the company possesses 1.53 times more current assets than current liabilities, which suggests a reasonable level of short-term liquidity despite the negative earnings. Additionally, the return on equity is not applicable, while the return on assets is -56.2%, revealing that the company's asset base is generating negative returns for its shareholders.

バリュエーション評価

The trailing P/E ratio and forward P/E ratio are both not applicable, as the company is reporting net losses, which renders traditional earnings-based valuation multiples meaningless for assessing expected earnings trajectory. The price-to-book ratio is listed as -0.00, a figure that typically indicates a negative book value per share, suggesting that the company's assets on the balance sheet are insufficient to cover its liabilities, or that the data point represents a null value in the reporting system. Since the price-to-sales ratio and EV/EBITDA metrics are not available in the provided facts, alternative valuation comparisons with peers cannot be established using these specific ratios. The 52-week high and 52-week low are both recorded as $0.00, which precludes any calculation of where the current price sits relative to a trading range or indicates a suspension of trading or a lack of price data for the specified period. With a beta of 0.79, the stock theoretically exhibits lower volatility relative to the broader market, as a beta below 1.0 implies that the security's price movements are less sensitive to systemic market shifts. However, given the zero high and low data points, the practical interpretation of this volatility metric is constrained by the absence of historical price data in the current reporting window.

Growth & Income

The company experienced a year-over-year revenue growth of -82.8%, while the earnings growth rate is not applicable due to the lack of prior comparable earnings data or the magnitude of the loss. This contraction in revenue suggests a decline in sales or commercialization activity, and without earnings growth to offset this decline, the financial picture points to significant headwinds in the top line. As a non-dividend payer, Clene Inc. does not distribute a dividend yield or payout ratio, as these metrics are not applicable to a company with negative net income and a lack of retained earnings. Consequently, the company must rely entirely on reinvesting its limited cash reserves and potentially external capital raises to fund its clinical trials and operational expenses rather than returning value to shareholders through dividends. The overall growth and income profile is characterized by negative revenue expansion and an absence of distributable earnings, indicating a capital-intensive phase where value creation depends on future clinical outcomes rather than current cash flow generation.